With our expertise and extensive experience in the field of gastrointestinal disease research, Ace Therapeutics aims to provide our clients with effective new drug development research solutions to advance the development of prokinetic drugs for gastrointestinal diseases.
Introduction to Gastrointestinal Prokinetic Drugs
Prokinetic drugs play an important role in the treatment of gastrointestinal diseases by improving digestive function, relieving associated symptoms and promoting nutrient absorption. These drugs can be applied to diseases such as dyspepsia, gastrointestinal motility disorders, pancreatic insufficiency and intestinal flora disorders.
Figure 1. Algorithm for the diagnosis and treatment of functional dyspepsia (FD). (Miwa H., et al., 2022)
Types of Prokinetic Drugs We Can Develop
- Promotility Drugs
During the development process of novel gastrointestinal motility drugs, we can provide clients with relevant preclinical efficacy evaluation services, such as observing the effect of the contractile function of intestinal smooth muscle on isolated intestinal segments of experimental animals.
- Digestive Enzyme Formulations
We empower clients to develop digestive enzyme formulations through comprehensive development and evaluation services. These services support the development of targeted solutions that address digestive enzyme deficiencies, optimize nutrient absorption, and meet the specific needs of diseases like pancreatic insufficiency and inadequate bile secretion.
- Bile Acid Drugs
For developing novel bile acid drugs, we are able to provide our clients with preclinical efficacy study services, including studies on the binding ability and affinity of the drug to bile acid receptors, the regulatory effects of the drug on key enzymes of bile acid synthesis, as well as in vivo efficacy evaluations in animal models of bile acid metabolism-related diseases.
What Can We Do for the Development of Gastrointestinal Prokinetic Drugs?
In Vitro Studies
We conduct in vitro experiments to study the effects of prokinetic drugs on enzyme activity, food metabolism and digestion and absorption in a simulated digestive environment.
- Digestive Enzyme Activity Assay
Prepare simulated gastric or intestinal fluids under in vitro conditions, add prokinetic agents, and measure the breakdown products of digestive substrates (like amino acids, glucose, or fatty acids).
Evaluate the effect of the drug on the activity of digestive enzymes such as pepsin, trypsin, amylase, or lipase.
- Simulated Digestion Experiment
Study the effect of prokinetic agents on food digestion by adding standard foods with prokinetic agents in an in vitro environment that mimics gastric or intestinal fluids, observe the facilitation of food digestion, and measure the decomposition products of the food.
In Vivo Studies
We conduct in vivo experiments to assess the actual efficacy of prokinetic drugs in promoting digestion, improving gastrointestinal function and alleviating dyspepsia, mainly through animal models.
- Gastric Emptying Assay
Assess the effect of prokinetic agents on the rate of gastric emptying by feeding food with tracers.
Track the emptying of gastric contents using fluorescent or radioactive markers.
- Nutrient Absorption Measurement
Collect blood or tissue samples from animals after the experiment to determine amino acid, glucose, and fatty acid concentrations, and test whether the drug promotes the absorption of digestive products.
- Gastrointestinal Motility Measurement
Measure the transit time through the digestive tract by giving animals a dye or radioactive marker orally to see if the drug modulates gastrointestinal motility.
By providing comprehensive in vitro and in vivo evaluation services, Ace Therapeutics helps pharmaceutical companies and research organizations develop novel therapeutics and facilitates the development of new drugs for the treatment of gastrointestinal diseases. If you are interested in our services, please do not hesitate to contact us.
Reference
- Miwa, H.; et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021. J Gastroenterol. 2022, 57(2):47-61.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
